Cargando…
Individualised benefit–harm balance of aspirin as primary prevention measure – a good proof-of-concept, but could have been better…
Guidelines from different organisations regarding the use of aspirin for primary prevention vary despite being based on similar evidence. Translating these in practice presents a further major challenge. The benefit–harm balance tool developed by Puhan et al. (BMC Med 13:250, 2015) for aspirin can o...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4936221/ https://www.ncbi.nlm.nih.gov/pubmed/27383519 http://dx.doi.org/10.1186/s12916-016-0648-9 |